Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).
Paradigm Biopharmaceuticals has advised holders of its PAROA quoted options that 97,358,215 options will expire at 5pm AEDT on 11 February 2026, with trading in these options to cease on 5 February 2026. Option holders have been notified that each option is exercisable at $0.65 into fully paid ordinary shares, with the potential issue of an equal number of shares and 48,679,107 piggyback options exercisable at $1.00 by February 2028, although the current share price of $0.35 sits below the exercise price; any options not exercised with cleared funds by the deadline will lapse unexercised, and there is no underwriting in place, leaving final take-up entirely dependent on investor demand.
The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.32 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Ltd (ASX:PAR) is a late-stage drug development company focused on discovering, developing and delivering pharmaceutical therapies to improve patients’ health and quality of life. Its current lead programs centre on injectable (subcutaneous) pentosan polysulfate sodium (iPPS), targeting inflammatory diseases such as osteoarthritis, where it is in phase 3 trials, and mucopolysaccharidosis, where it is in phase 2 trials.
Average Trading Volume: 1,029,502
Technical Sentiment Signal: Hold
Current Market Cap: A$154.3M
For an in-depth examination of PAR stock, go to TipRanks’ Overview page.